You searched for: opioidagonister (Danska - Engelska)

samtidig anvendelse af partielle opioidagonister/-antagonister (fx buprenorphin, nalbuphin, pentazocin) anbefales ikke.
the concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended.

samtidig brug af partielle opioidagonister/antagonister (f.eks. buprenorphin, nalbuphin, pentazocin) frarådes.
the concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended.

samtidig brug af partielle opioidagonister/antagonister (f.eks. buprenorphin, nalbuphin, pentazocin) anbefales ikke.
the concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended.

21 samtidig anvendelse af partielle opioidagonister / - antagonister (f. eks. buprenorphin, nalbuphin, pentazocin) frarådes.
21 the concomitant use of partial opioid agonists/ antagonists (e. g. buprenorphine, nalbuphine, pentazocine) is not recommended.

intravenøst eller intranasalt misbrug af suboxone forventes at være mindre sandsynligt end af buprenorphin alene, idet naloxonen i suboxone kan udløse abstinenssymptomer hos personer, der er afhængige af heroin, methadon eller andre opioidagonister.
intravenous or intranasal misuse of suboxone is expected to be less likely than buprenorphine alone since the naloxone in suboxone can precipitate withdrawal in individuals dependent on heroin, methadone, or other opioid agonists.

det anbefales at bruge en opioidantagonist (dvs. naloxon) på trods af den beskedne virkning, det kan have på at modvirke respirationssymptomerne af buprenorphin i forhold til stoffets virkning på rene opioidagonister.
use of an opioid antagonist (i.e., naloxone) is recommended, despite the modest effect it may have in reversing the respiratory symptoms of buprenorphine compared with its effects on full agonist opioid agents.

til denne form for farmakologisk behandlinganvendes typisk naltrexon (en antagonist) eller en affølgende opioidagonister: metadon, buprenorfin,dihydrocodein, heroin eller depotmorfin.
however, inrecent years treatment options have widened. by 2002 allof the ‘old’ 15 member states except the netherlands and

anvendelse af en opioidantagonist (f. eks. naloxon) anbefales på trods af den beskedne effekt, det kan have i forhold til at ophæve respirationssymptomerne af buprenorphin sammenlignet med dets virkning på fulde opioidagonister.
use of an opioid antagonist (i. e., naloxone) is recommended, despite the modest effect it may have in reversing the respiratory symptoms of buprenorphine compared with its effects on full agonist opioid agents.